



VitroScreen excellence in *in vitro* science

Emerging Trend in Use of Skin Care and Sun Care, A Boost to Upgrade *in vitro* Strategies for Local Tolerance Evaluation of Ingredients



Roso Alicia¹, Puginier Mickaël¹, Bergal Mathilde¹, De Servi Barbara², Ceriotti Laura², Meloni Marisa² ¹Seppic, 92257 La Garenne Colombes, France ; ²VitroScreen, 20149 Milan, Italy

Introduction

Formulation trends or new uses are also an opportunity to improve technical knowledge and upgrade practices. In recent years, the popularity of aerosol sprays has increased worldwide. Out of traditional use in fragrances, deodorant/antiperspirant, hairspray and spring waters, **aerosol format expanded into new categories**, **especially skin care and sun protection**. This trend raises a **new challenge for local tolerance assessment as some ingredients**, not present in traditional aerosol compositions, can be **occasionally or frequently in contact with the upper airways**.

- **Objectives** Investigate the tolerance of some key ingredients on a reconstructed upper airway epithelium model
 - Ultimate goal: facilitate, at early development stages, the selection and appropriate dosages of ingredients widely used in skin care and sun care sprays.

Materials & methods

O Investigation of model sensitivity with aerosol sprayable skin care benchmarks (expected good tolerance levels according to marketing claims).

2 Validation of the experiments with negative and positive controls.

Oxalic acid selected as a known respiratory irritant [1] used at reduced dosage (2mg/mL), intended to induce a slight effect (IC-75=1.16mg/mL; Concentration required to reduce viability to 75%; MTT measurement).

Formula	Туре	Main components	Skin target		
Benchmark1	Oil in water (O/W)	Isopropyl Palmitate, Petrolatum, Dimethicone, Hydrolyzed Hyaluronic Acid, Isohexadecane, C12-20 Alkyl Glucoside, Polysorbate 60, Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, C14-22 Alcohols, Preservative system and Fragrance	Moisturizing body mist		
Benchmark2	emulsion	Dipropylene Glycol, Isostearyl Isostearate, Sucrose Stearate, Squalane, Pentylene Glycol, Cellulose Gum, Polyacrylate Crosspolymer-6, 5 Active Ingredients: Plant Extracts & Vitamin, No Preservative, No Fragrance	Soothing / for sensitive skin		
Controls Negative Positive		Phosphate-Buffered Saline (PBS)			
		Oxalic acid (2mg/mL)			

B Evaluation of ingredients with key functionality in skin care and sun care formulations selected according to: well known safety and local tolerance profiles, texture and rheology behaviour suitable for aerosol format, versatility in skin and sun care usages.

Category	Code	Structure / INCI		
Emollient	Emo	C15-19 Alkane		
O/W	Emul1	C12-20 Alkyl Glucoside, C14-22 Alcohols		
Emulsifier	Emul2	C20-22 Alcohols & C20 Glucoside		
RM1		Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer		
Rheology modifier	RM2	Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer, Isohexadecane, Polysorbate 60		

Results & Discussions

Model sensitivity and experiments validation

- Protocol validated on independant experiments (1 and 2) using well known respiratory irritant chemicals (data not shown)
- Significant and reproducible effects obtained for the positive control.
- High sensitivity of the model confirmed by the results on the benchmarks with significant effects: • Cell viability not affected (both benchmarks),
- Benchmark 1 affected cellular membrane integrity at 3 hours and increased inflammatory signal. After 24 hours, inflammation was maintained while LDH release returned to normal level.
- Benchmark 2 reduced membrane integrity and epithelium barrier functions up to 24 hours.

Items	Viability	LDH release (mU/mL)		TEER	IL-8 release (pg/mL)		Histology
	(NC %)	3h	24h	(NC %)	3h	24h	(score)
Negative control (Experiment 1/ Experiment 2)	100	0/1	0/26	100	2 800/2 002	7 300/10 600	0-1/0
Positive control (Experiment 1/ Experiment 2)	78*/73	27*/46*	99*/184*	10*/18*	15 900*/13 700*	60 000*/50 200*	2-3/3
Benchmark1 (Experiment 1/ Experiment 2)	100/100	5*/9*	24/11	86/66	5 354*/ND	20 953*/ND	0-1/ND
Benchmark2 (Experiment 1/ Experiment 2)	100	13*	63*	15*	748	12 138	2

Controls & Benchmarks results * p<0,05 T-test compared to negative control; ND: Not Done

Viability	LDH release (mU/mL)		TEER	IL-8 release (pg/mL)		Histology
(NC %)	3h	24h	(NC %)	3h	24h	(score)
100	0/1	0/26	100	2 800/2 002	7 300/10 600	0-1/0
77*/100	2/5	3/0	114/148	ND/0	ND/2075	ND/1
93	3	34	99	3 420	21 884*	0-1
100	4	5	66	2 052	4 871	0-1
65	5	51	105	2 529	18 259	1
79/100	2/3	8/7	131/92	ND/863	ND/10 328	ND/1
	(NC %) 100 77*/100 93 100 65	(NC %) 3h 100 0/1 77*/100 2/5 93 3 100 4 65 5	(NC %) 3h 24h 100 0/1 0/26 77*/100 2/5 3/0 93 3 34 100 4 5 65 5 51	(NC %) 3h 24h (NC %) 100 0/1 0/26 100 77*/100 2/5 3/0 114/148 93 3 34 99 100 4 5 66 65 5 51 105	(NC %) 3h 24h (NC %) 3h 100 0/1 0/26 100 2 800/2 002 77*/100 2/5 3/0 114/148 ND/0 93 3 34 99 3 420 100 4 5 66 2 052 65 5 51 105 2 529	(NC %) 3h 24h (NC %) 3h 24h 100 0/1 0/26 100 2 800/2 002 7 300/10 600 77*/100 2/5 3/0 114/148 ND/0 ND/2075 93 3 34 99 3 420 21 884* 100 4 5 66 2 052 4 871 65 5 51 105 2 529 18 259

Ingredients results * p<0,05 T-test compared to negative control; ND: Not Done


Limited effects of ingredients considering controls.

Emollient did not significantly affect the evaluated parameters. Decrease in viability in experiment 1 considered as biologically non significant (variability within replicates and experiments).

Emulsifiers, differing only in the length of the fat chain, preserved cellular viability, tissue organisation

4 Methodology:

The protocol was developed to mimic limited exposure time on the upper airway.



and barrier function. Emul1 slightly increased the LDH release and inflammatory response after 24h.
Only RM1, at 24h, affected viability and LDH release (non-statistically) and IL-8 expression (p<0.05).
RM1 and RM2 provided same histology score of 1 (preserved overall morphology *versus* negative control, visible cilia, goblet cells with regular shape, distribution and mucus).

Discussion: Attempted tolerance scale

Viability selected as entry parameter for irritation, others equally weighted to determine tolerance levels.

- Good: Parameters not significantly different from the negative control
- Acceptable: Viability comparable to the negative control. One or several parameters with significant effects (acceptability according to Benchmarks)
- **Poor:** significant decrease in viability and marked effects on one or several other parameters.

Emul1, included in Benchmark 1, provided the same type of effects with expected similar conclusion. Sensitivity of 3D reconstructed epithelia to surfactants is well recognized [2] and found both in Benchmarks 1 and 2. Even if Emul1 provided an acceptable conclusion, Emul2 can be preferred for such aerosol sprays.

Items	Tolerance conclusion		
Negative control	Good		
Positive control	Poor		
Benchmark1	Acceptable		
Benchmark2	Acceptable		
Emo	Good		
Emul1	Acceptable		
Emul2	Good		
RM1	Acceptable		
RM2	Good		

Tentative tolerance conclusion

Higher polymer concentration of RM1 compared to RM2 can partly explain the different conclusions. Mucoadhesive properties of RM1 [3] could have contributed to wash-off disturbance ► overestimated effects. On the contrary, RM2 was easily washed off (more fluid gel/quick break effect).



- This 3D in vitro model represents a promising screening tool to assess the local tolerance of ingredients that may frequently or occasionally come into contact with the upper airway, first line of defense in the respiratory system.
- Multiparametric analysis increases model sensitivity and opens perspective to determine suitable well-tolerated ingredient doses. Further investigations on diverse chemical structures covering all ingredients categories should be carried out as well as dose-response effects. Due to its high sensitivity, this model could be used to predict the tolerance level of ingredient combinations, from the very beginning of aerosol formulations development.

References: 1. Maione AG, Jackson GR, Vinall JL, Simpson H, Storey EL, Debatis M, Klausner M, Roper C, Hayden PJ; (2018) Comparative inhalation toxicity testing using in vitro organotypic rat and human airway epithelial models. 20th ESTIV Congress, poster 135, Berlin, Germany. 2. Roso A, Puginier M, Bergal M, Nunzi F, Alonso A; (2021) In vitro Approach to Assess Local Tolerance of Ingredients Dedicated to Specific Topical Care Applications. J Dermatol & Skin Sci. 3(1):30-48.

3. Denis A, Coudert C, Despax S, Ben Arous J, Bulcourt C, Roso A; (2019) Innovative Rheology Modifiers for Mucosal Formulations. Skin and Formulation 5th Symposium Reims, France.